Soft tissue
Targeted testing for improved patient management
Sarcoma can occur in any of the soft tissue in the body, as well as bones, and is the fourth most common type of pediatric cancer.1 Because there are more than 100 subtypes of sarcoma, many with overlapping features, genetic testing can clarify and improve diagnostic accuracy and overall patient management.
SOFT TISSUE test menu
Soft tissue
Our sarcoma gene fusion panel detects fusions described in 100+ subtypes of bone and soft tissue tumors. Using whole transcriptome RNA sequencing, this assay can detect gene fusions that occur between both known and novel gene partners in 1,445 genes, offering the most comprehensive analysis of gene fusion in soft tissue and bone tumors available. RNA sequencing complements DNA-only sequencing, providing accurate detection of gene fusions — including novel fusion partners and breakpoints. By incorporating transcribed regions often missed by smaller targeted RNA-seq assays, this assay improves the ability to detect complex or hard-to-identify fusions.
Key testing
- MCRSP | MayoComplete Targeted RNA Sequencing Panel, Next-Generation Sequencing, Tumor
- Analyzes 1,445 genes for fusions associated with soft tissue and bone tumors.
- Assesses fusions described in 100+ subtypes of soft tissue and bone tumors.
- Validated for both FFPE tumor samples and cytology specimens.
- Aligns with updated guidelines for integrated molecular reporting established by the WHO, the National Comprehensive Cancer Network, and the College of American Pathologists.
Highlights
Learn more about how Mayo Clinic Laboratories approach to whole transcriptome RNA sequencing provides the most comprehensive detection of gene fusions in solid tumors through use of next-generation sequencing to identify fusions in 1,445 genes.
References
- Williams R, Fernandez-Pineda I, Gosain A. Pediatric Sarcomas. The Surgical Clinics of North America 2016-10-01, Volume 96, Issue 5, Pages 1107-1125.